The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Final results from ClarIDHy: ivosidenib in IDH1-mutated CCA
Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the final results of the ClarIDHy trial (NCT02989857): a Phase III, randomized, double-blind study of ivosidenib in patients with an isocitrate dehydrogenase 1 mutation (IDH) and previously treated cholangiocarcinoma (CCA). Progression-free survival (PFS) was 1.3 months greater in patients treated with ivosidenib than in the control group and the mean overall survival (OS) rate in the treatment group was more than twice that in the control group. Ivosidenib was generally well tolerated. The results of the ClarIDHy trial may facilitate the approval of ivosidenib for the treatment of mIDH1 CCA. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
